A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma
Clinical trial NCT05078593 · COMPLETED
Trial details
- NCT number
- NCT05078593
- Sponsor
- Shanghai Henlius Biotech
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-11
- Primary completion
- 2023-08-18
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.